NGRC Stock Overview
National Graphite Corp., through its subsidiary, Biotech Development Corp., operates as a biopharmaceutical risk/cost-sharing company.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
National Graphite Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.068 |
| 52 Week High | US$0.12 |
| 52 Week Low | US$0.038 |
| Beta | 0 |
| 1 Month Change | 11.48% |
| 3 Month Change | 43.19% |
| 1 Year Change | 17.04% |
| 3 Year Change | -47.69% |
| 5 Year Change | 88.89% |
| Change since IPO | -99.55% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| NGRC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -2.5% | -3.2% |
| 1Y | 17.0% | -3.7% | 19.3% |
Return vs Industry: NGRC exceeded the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: NGRC underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| NGRC volatility | |
|---|---|
| NGRC Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NGRC's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine NGRC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Ulrike Dickmann | n/a |
National Graphite Corp., through its subsidiary, Biotech Development Corp., operates as a biopharmaceutical risk/cost-sharing company. The company collaborates with clinical stage companies that develop new biological entities or new therapeutically platforms for the treatment of various diseases, rare diseases, and diseases with unmet needs. It is developing a drug candidate called ELAFIN, which is a human identic protein for the treatment of postoperative inflammatory complications.
National Graphite Corp. Fundamentals Summary
| NGRC fundamental statistics | |
|---|---|
| Market cap | US$10.49m |
| Earnings (TTM) | -US$1.97m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs NGRC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NGRC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.97m |
| Earnings | -US$1.97m |
Last Reported Earnings
May 31, 2015
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did NGRC perform over the long term?
See historical performance and comparison